Have your own idea? Try our Stock Screener
Norwegian (OSEAX) Biotech Industry Analysis
UpdatedMar 25, 2026
DataAggregated Company Financials
Companies9
- 7D-2.3%
- 3M0.3%
- 1Y30.3%
- YTD3.5%
Last week, the Biotech industry hasn't moved much but Hofseth BioCare is up 14% in that time. As for the the longer term, the industry is up 29% over the past 12 months. Earnings are forecast to grow by 9.2% annually.
Industry Valuation and Performance
Has the Norwegian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 25 Mar 2026 | NOK 5.6b | NOK 545.1m | -NOK 378,779,554.60 | 51.9x | -14.8x | 10.3x |
| Fri, 20 Feb 2026 | NOK 5.7b | NOK 611.1m | -NOK 365,247,791.02 | 59.4x | -15.5x | 9.3x |
| Sun, 18 Jan 2026 | NOK 5.5b | NOK 607.1m | -NOK 368,299,486.96 | 82.2x | -15x | 9.1x |
| Tue, 16 Dec 2025 | NOK 4.9b | NOK 607.5m | -NOK 368,951,795.54 | 79.7x | -13.3x | 8.1x |
| Thu, 13 Nov 2025 | NOK 4.9b | NOK 612.8m | -NOK 428,810,023.19 | 87.1x | -11.3x | 7.9x |
| Sat, 11 Oct 2025 | NOK 4.8b | NOK 612.9m | -NOK 520,116,283.67 | 255.8x | -9.3x | 7.9x |
| Mon, 08 Sep 2025 | NOK 4.7b | NOK 614.3m | -NOK 494,784,073.76 | 249.4x | -9.5x | 7.7x |
| Wed, 06 Aug 2025 | NOK 4.8b | NOK 886.5m | -NOK 749,071,323.68 | 232.3x | -6.4x | 5.4x |
| Fri, 04 Jul 2025 | NOK 4.8b | NOK 884.9m | -NOK 744,234,759.47 | 200.8x | -6.5x | 5.4x |
| Sun, 01 Jun 2025 | NOK 4.7b | NOK 886.0m | -NOK 747,610,808.40 | 186.3x | -6.3x | 5.3x |
| Tue, 29 Apr 2025 | NOK 4.6b | NOK 519.0m | -NOK 1,015,155,763.95 | 109.6x | -4.5x | 8.9x |
| Thu, 27 Mar 2025 | NOK 5.0b | NOK 520.9m | -NOK 1,098,569,647.48 | 114x | -4.6x | 9.6x |
| Sat, 22 Feb 2025 | NOK 5.4b | NOK 471.8m | -NOK 1,117,012,474.70 | 127.5x | -4.8x | 11.4x |
| Mon, 20 Jan 2025 | NOK 5.1b | NOK 458.0m | -NOK 1,077,341,624.02 | 154.5x | -4.7x | 11.2x |
| Wed, 18 Dec 2024 | NOK 4.8b | NOK 456.9m | -NOK 1,067,807,854.22 | 153.4x | -4.5x | 10.5x |
| Fri, 15 Nov 2024 | NOK 3.5b | NOK 484.4m | -NOK 1,070,732,026.35 | 152.9x | -3.3x | 7.3x |
| Sun, 13 Oct 2024 | NOK 5.1b | NOK 470.4m | -NOK 1,060,957,315.60 | 57.6x | -4.8x | 10.8x |
| Tue, 10 Sep 2024 | NOK 5.4b | NOK 471.4m | -NOK 1,059,798,838.05 | 62.9x | -5.1x | 11.5x |
| Thu, 08 Aug 2024 | NOK 8.1b | NOK 515.6m | -NOK 1,048,408,414.91 | 70.5x | -7.8x | 15.8x |
| Sat, 06 Jul 2024 | NOK 8.6b | NOK 512.7m | -NOK 1,037,768,038.42 | 68x | -8.3x | 16.7x |
| Mon, 03 Jun 2024 | NOK 9.5b | NOK 629.6m | -NOK 937,100,071.72 | 38.1x | -10.1x | 15.1x |
| Wed, 01 May 2024 | NOK 8.5b | NOK 661.5m | -NOK 965,509,724.54 | 36.2x | -8.8x | 12.8x |
| Fri, 29 Mar 2024 | NOK 9.2b | NOK 658.5m | -NOK 944,091,189.40 | 40.9x | -9.8x | 14x |
| Sun, 25 Feb 2024 | NOK 15.2b | NOK 672.2m | -NOK 1,004,577,330.24 | 40.3x | -15.1x | 22.6x |
| Tue, 23 Jan 2024 | NOK 16.2b | NOK 657.3m | -NOK 1,361,662,653.00 | 59.2x | -11.9x | 24.7x |
| Thu, 21 Dec 2023 | NOK 15.7b | NOK 654.3m | -NOK 1,352,909,470.00 | 59.4x | -11.6x | 23.9x |
| Sat, 18 Nov 2023 | NOK 15.2b | NOK 657.5m | -NOK 1,369,872,089.00 | 55.5x | -11.1x | 23.2x |
| Mon, 16 Oct 2023 | NOK 15.0b | NOK 627.4m | -NOK 1,465,353,107.00 | 48.7x | -10.2x | 23.9x |
| Wed, 13 Sep 2023 | NOK 15.4b | NOK 624.3m | -NOK 1,458,322,595.00 | 56.9x | -10.6x | 24.7x |
| Fri, 11 Aug 2023 | NOK 16.4b | NOK 555.9m | -NOK 1,455,220,569.00 | 52.6x | -11.3x | 29.5x |
| Sun, 09 Jul 2023 | NOK 15.1b | NOK 560.3m | -NOK 1,473,429,891.00 | 59.7x | -10.3x | 27x |
| Tue, 06 Jun 2023 | NOK 16.7b | NOK 564.9m | -NOK 1,501,144,398.00 | 61.4x | -11.2x | 29.6x |
| Thu, 04 May 2023 | NOK 16.5b | NOK 542.4m | -NOK 1,448,871,021.00 | 31.3x | -11.4x | 30.3x |
| Sat, 01 Apr 2023 | NOK 15.4b | NOK 549.2m | -NOK 1,547,316,135.00 | 32.9x | -10x | 28.1x |
Price to Earnings Ratio
-10x
Current Industry PE
- Investors are pessimistic on the Norwegian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 15.3x is higher than the industry's current PS ratio of 10.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.
Industry Trends
Which industries have driven the changes within the Norwegian Healthcare industry?
| NO Market | -0.33% | |
| Healthcare | -1.89% | |
| Biotech | -2.29% | |
| Biotech | -2.29% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| HBC Hofseth BioCare | NOK 1.54 | 14.1% +NOK 78.1m | -35.0% | PS2.5x | |
| NYKD Nykode Therapeutics | NOK 3.05 | 3.3% +NOK 32.0m | 34.7% | PS226.5x |